Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.08). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.47 million. The firm's revenue for the quarter was down 59.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.94) EPS. On average, analysts expect Crinetics Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Up 1.7 %

Shares of CRNX traded up $0.99 during trading hours on Tuesday, reaching $57.81. 326,968 shares of the company traded hands, compared to its average volume of 783,280. The firm has a market cap of $4.63 billion, a price-to-earnings ratio of -15.09 and a beta of 0.62. The stock's fifty day moving average price is $53.85 and its 200 day moving average price is $50.35. Crinetics Pharmaceuticals has a 12-month low of $25.75 and a 12-month high of $60.04.

Insider Activity at Crinetics Pharmaceuticals

In related news, CFO Marc Wilson sold 25,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $51.11, for a total value of $1,277,750.00. Following the completion of the sale, the chief financial officer now directly owns 111,092 shares in the company, valued at $5,677,912.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Marc Wilson sold 25,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $51.11, for a total value of $1,277,750.00. Following the transaction, the chief financial officer now directly owns 111,092 shares of the company's stock, valued at approximately $5,677,912.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen F. Betz sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $53.19, for a total value of $159,570.00. Following the sale, the insider now directly owns 69,611 shares of the company's stock, valued at $3,702,609.09. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,410 shares of company stock valued at $2,275,929 in the last ninety days. Corporate insiders own 6.00% of the company's stock.

Wall Street Analysts Forecast Growth

CRNX has been the topic of several research reports. Cantor Fitzgerald restated an "overweight" rating and set a $90.00 price objective on shares of Crinetics Pharmaceuticals in a report on Monday, September 16th. JPMorgan Chase & Co. lifted their price objective on Crinetics Pharmaceuticals from $47.00 to $54.00 and gave the company an "overweight" rating in a report on Tuesday, July 9th. Oppenheimer reiterated an "outperform" rating and set a $73.00 target price (down from $74.00) on shares of Crinetics Pharmaceuticals in a report on Friday, August 9th. JMP Securities restated a "market outperform" rating and issued a $80.00 price target on shares of Crinetics Pharmaceuticals in a report on Friday, September 27th. Finally, HC Wainwright increased their price objective on shares of Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the company a "buy" rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $68.55.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.